Tahir Amin: Addressing Drug Prices in the United States
Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses how to address high US drug prices.
Transcript:
What would have the biggest effect on drug pricing in America?
I think with the drug pricing debates there are a lot of options being pulled—policy levers. We fundamentally believe that unless we get to the route of the problem, which is the overpatenting problem, we will never solve the drug pricing problem. It will always remain in the powers of the pharmaceutical companies.
We have to restore much needed balance between the patent system and its incentives with how the market is failing at the moment for the public, because 1 in 4 Americans are having to make difficult choices between filling their prescriptions or putting food on the table, and we know that, according to statistics, drug prices are going to double by 2025.
We believe that there needs to be a significant correction in how we hand out these monopolies, because these monopolies are getting longer and they’re becoming that much more difficult to allow for competition in the market.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
